Physician profile
Alex Pham
NPI 1043813132
$18,198.03
in general payments reported to CMS, 2019-2025
55 companies · $3,590 in 2025
The $3,590 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,676 · 2022: $3,649 · 2023: $4,110 · 2024: $4,173 · 2025: $3,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,873.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,713.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,726.23 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,324.82 | 2021-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $1,284.04 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Ibsa Pharma INC. | $1,048.86 | 2021-2025 | Tirosint, Tirosint, Licart |
| Corcept Therapeutics | $956.74 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $955.41 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $757.94 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $700.66 | 2021-2025 | Saphnelo, Farxiga |
| Glaxosmithkline, LLC. | $678.48 | 2021-2025 | Benlysta |
| Radius Health, INC. | $539.71 | 2021-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $478.82 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $440.68 | 2021-2025 | Strensiq |
| Pfizer INC. | $390.70 | 2022-2025 | |
| Abbott Laboratories | $382.53 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $377.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Tandem Diabetes Care, INC. | $309.95 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $304.97 | 2021-2023 | Tepezza, Krystexxa |
| Dexcom, INC. | $290.43 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $247.96 | 2022-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $195.87 | 2023-2025 | Yorvipath |
| Almatica Pharma LLC | $172.17 | 2024-2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.62 | 2022-2024 | Cyltezo |
| Mannkind Corporation | $147.97 | 2021-2024 | |
| Zealand Pharma US, INC. | $112.97 | 2021 | |
| Embecta Corp. | $109.02 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Merck Sharp & Dohme LLC | $105.69 | 2021-2023 | Steglatro, Januvia |
| Medtronic, INC. | $97.66 | 2021-2023 | Vanta Adaptivestim |
| Janssen Biotech, INC. | $88.89 | 2022-2023 | Simponi, Simponi Aria, Stelara |
| Ultragenyx Pharmaceutical INC. | $84.82 | 2021-2023 | |
| Ascensia Diabetes Care US INC. | $82.59 | 2023-2024 | |
| Abbvie INC. | $79.19 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $72.29 | 2024-2025 | Tlando |
| Averitas Pharma INC. | $68.39 | 2023-2024 | Qutenza |
| Antares Pharma, INC. | $65.28 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Neurocrine Biosciences, INC. | $65.12 | 2025 | |
| Sobi, INC | $51.97 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $50.04 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $48.10 | 2023 | Arcalyst |
| Kyowa Kirin, INC. | $45.48 | 2023-2025 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $43.05 | 2021 | |
| Beta Bionics, INC. | $42.99 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ucb, INC. | $38.74 | 2023-2025 | Bimzelx, Cimzia |
| Amryt Pharma Holdings LTD | $30.14 | 2022 | |
| Sanofi Pasteur INC. | $29.58 | 2025 | |
| Cequr Corporation | $25.61 | 2023 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $24.02 | 2024 | Nexletol |
| Chiesi USA, INC. | $23.28 | 2025 | Mycapssa |
| Ionis Pharmaceuticals, INC. | $22.18 | 2025 | Tryngolza |
| Aimmune Therapeutics, INC. | $18.63 | 2024 | |
| Mylan Institutional INC. | $18.58 | 2023 | Hulio |
| Rhythm Pharmaceuticals, INC. | $17.55 | 2025 | Imcivree |
| Novartis Pharmaceuticals Corporation | $16.62 | 2022 | |
| Eusa Pharma (US) LLC | $15.89 | 2022 | |
| Amarin Pharma, INC. | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.